Akari Therapeutics Plc — Director's Dealing 2025

Dec 19, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Akari Therapeutics Plc (AKTX)
CIK: 0001541157
Period of Report: 2025-12-16

Reporting Person: Gaslightwala Abizer (Director, CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-12-16	Warrants to purchase American Depositary Shares ("ADRs")	$0.3883	P	309328	Acquired		American Depositary Shares representing Ordinary Shares (309328)	Direct
2025-12-16	Pre-Funded Warrants to purchase ADRs	$0.0000	P	309328	Acquired		American Depositary Shares representing Ordinary Shares (309328)	Direct
2025-12-16	Warrants to purchase ADRs	$0.3883	P	773323	Acquired		American Depositary Shares representing Ordinary Shares (773323)	Direct
2025-12-16	Pre-Funded Warrants to purchase ADRs	$0.0000	P	773323	Acquired		American Depositary Shares representing Ordinary Shares (773323)	Direct

Footnotes

F1: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer.

F2: On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 309,328 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 309,328 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended.

F3: The Series G Warrants and the PIPE PFW shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised.

F4: The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041.

F5: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 773,323 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 804,790 ADSs (the "Note Exchange Unregistered Warrants").

F6: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised.

F7: Conversion Exercise Price of Security is $0.00001